Literature DB >> 23053738

Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors.

Ori Kalid1, Dora Toledo Warshaviak, Sharon Shechter, Woody Sherman, Sharon Shacham.   

Abstract

We present the Consensus Induced Fit Docking (cIFD) approach for adapting a protein binding site to accommodate multiple diverse ligands for virtual screening. This novel approach results in a single binding site structure that can bind diverse chemotypes and is thus highly useful for efficient structure-based virtual screening. We first describe the cIFD method and its validation on three targets that were previously shown to be challenging for docking programs (COX-2, estrogen receptor, and HIV reverse transcriptase). We then demonstrate the application of cIFD to the challenging discovery of irreversible Crm1 inhibitors. We report the identification of 33 novel Crm1 inhibitors, which resulted from the testing of 402 purchased compounds selected from a screening set containing 261,680 compounds. This corresponds to a hit rate of 8.2 %. The novel Crm1 inhibitors reveal diverse chemical structures, validating the utility of the cIFD method in a real-world drug discovery project. This approach offers a pragmatic way to implicitly account for protein flexibility without the additional computational costs of ensemble docking or including full protein flexibility during virtual screening.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053738     DOI: 10.1007/s10822-012-9611-9

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  65 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

Review 2.  Leucine-rich nuclear-export signals: born to be weak.

Authors:  Ulrike Kutay; Stephan Güttinger
Journal:  Trends Cell Biol       Date:  2005-03       Impact factor: 20.808

3.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

4.  Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.

Authors:  Timothy I Richardson; Scott A Frank; Minmin Wang; Christian A Clarke; Scott A Jones; Bai-Ping Ying; Dan T Kohlman; Owen B Wallace; Timothy A Shepherd; Robert D Dally; Alan D Palkowitz; Andrew G Geiser; Henry U Bryant; Judith W Henck; Ilene R Cohen; Daniel G Rudmann; Denis J McCann; David E Coutant; Samuel W Oldham; Conrad W Hummel; Kin C Fong; Ronald Hinklin; George Lewis; Hongqi Tian; Jeffrey A Dodge
Journal:  Bioorg Med Chem Lett       Date:  2007-04-24       Impact factor: 2.823

5.  Identifying and characterizing binding sites and assessing druggability.

Authors:  Thomas A Halgren
Journal:  J Chem Inf Model       Date:  2009-02       Impact factor: 4.956

6.  1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.

Authors:  I K Khanna; R M Weier; Y Yu; X D Xu; F J Koszyk; P W Collins; C M Koboldt; A W Veenhuizen; W E Perkins; J J Casler; J L Masferrer; Y Y Zhang; S A Gregory; K Seibert; P C Isakson
Journal:  J Med Chem       Date:  1997-05-23       Impact factor: 7.446

7.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

8.  Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.

Authors:  Tine Van Neck; Christophe Pannecouque; Els Vanstreels; Miguel Stevens; Wim Dehaen; Dirk Daelemans
Journal:  Bioorg Med Chem       Date:  2008-09-20       Impact factor: 3.641

9.  Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta.

Authors:  J Sun; M J Meyers; B E Fink; R Rajendran; J A Katzenellenbogen; B S Katzenellenbogen
Journal:  Endocrinology       Date:  1999-02       Impact factor: 4.736

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  29 in total

Review 1.  Nuclear export mediated regulation of microRNAs: potential target for drug intervention.

Authors:  Irfana Muqbil; Bin Bao; Abdul Badi Abou-Samra; Ramzi M Mohammad; Asfar S Azmi
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 2.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

3.  Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Authors:  Sabiha Kazim; Mokenge P Malafa; Domenico Coppola; Kazim Husain; Sherma Zibadi; Trinayan Kashyap; Marsha Crochiere; Yosef Landesman; Tami Rashal; Daniel M Sullivan; Amit Mahipal
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

4.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments.

Authors:  G Madhavi Sastry; Matvey Adzhigirey; Tyler Day; Ramakrishna Annabhimoju; Woody Sherman
Journal:  J Comput Aided Mol Des       Date:  2013-04-12       Impact factor: 3.686

Review 5.  Atomic basis of CRM1-cargo recognition, release and inhibition.

Authors:  Ho Yee Joyce Fung; Yuh Min Chook
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

Review 6.  Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Authors:  Irfana Muqbil; Jack Wu; Amro Aboukameel; Ramzi M Mohammad; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2014-06-17       Impact factor: 15.707

7.  A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.

Authors:  Iraia García-Santisteban; Igor Arregi; Marián Alonso-Mariño; María A Urbaneja; Juan J Garcia-Vallejo; Sonia Bañuelos; Jose A Rodríguez
Journal:  Cell Mol Life Sci       Date:  2016-06-16       Impact factor: 9.261

8.  Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Authors:  Edward F Attiyeh; John M Maris; Richard Lock; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Gorlick; E Anders Kolb; Stephen T Keir; Jianrong Wu; Yosef Landesman; Sharon Shacham; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2015-09-23       Impact factor: 3.167

Review 9.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

10.  Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.

Authors:  Asfar S Azmi; Husain Yar Khan; Irfana Muqbil; Amro Aboukameel; Jasper E Neggers; Dirk Daelemans; Amit Mahipal; Gregory Dyson; Mandana Kamgar; Mohammad Najeeb Al-Hallak; Anteneh Tesfaye; Steve Kim; Vinod Shidham; Ramzi M Mohammad; Philip A Philip
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.